Salvato in:
| Autore principale: | |
|---|---|
| Natura: | Artículo científico |
| Lingua: | en |
| Pubblicazione: |
Sociedad Latinoamericana de Hipertensión
2006
|
| Soggetti: | |
| Accesso online: | https://www.redalyc.org/articulo.oa?id=170217084004 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
Sommario:
- Metformin plus low glimepiride doses, improve significantly HOMA(ir) and HOMA(¿cell) without hyperinsulinemia in patients with type 2 diabetes Valmore J. Bermúdez Fernando A. Bermúdez Clímaco Cano Mayerlim T. Medina Miguel A. Lemus Elliuz M. Leal Hamid A. Seyfi Mayela C. Cabrera Merlyn J. Ambard Aida J. Souki Ana C. Ciszek Raquel A. Cano Carlos A. Briceño S. Medicina HOMA Metformin Glimepiride Type 2 diabetes insulinresistance Type 2 Diabetes mellitus is characterized by insulin resistance and defects in insulin secretion. These variables have been studied by the euglycemic/hyperinsulinemic clamp and MinMod, which difficult the HOMAIR and HOMA¿cell failure study in clinical practice. The aim of this study was to evaluate three different anti-diabetic therapeutic options using a mathematical model (Homeostasis model assessment, HOMA). Seventy type 2 diabetic patients were randomly assigned one of the next therapeutic options: A) Metformin + ADA Diet + Physical activity (Walk, 60 minutes/day). B) Metformin + Glimepiride + ADA Diet + Physical activity. C) Only ADA diet + Physical activity. A blood sample was taken before and after the treatment to determine basal and post-prandial blood glucose, basal insulin and HbA1c and to calculate HOMA¿cell and HOMAIR. Before treatment basal and post-prandial levels of glucose, HbA1c, basal insulin and HOMAIR and HOMA'cell were significantly different when compared to after treatment levels for each group (p<0.01). Significant differences were also found when comparing basal blood glucose reduction (51.8 %; p<0.01), post-prandial blood glucose (55.0%; p<0.05), and HOMAIR (65.3%; p<0.01) of group B (Metformin + low glimepiride dose) with the other therapeutic options. We conclude that metformin plus glimepiride at a low dose is a more effective treatment for type 2 diabetes than other therapeutic options. HOMAIR and HOMA'cell are inexpensive and reliable methods to study HOMAIR and HOMA'cell function in DM2. 2006 artículo científico 1856-4550 https://www.redalyc.org/articulo.oa?id=170217084004 en http://www.redalyc.org/revista.oa?id=1702 Revista Latinoamericana de Hipertensión application/pdf Sociedad Latinoamericana de Hipertensión Revista Latinoamericana de Hipertensión (República Bolivariana de Venezuela) Num.4 Vol.1